BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35776191)

  • 1. RNA-sequencing of myxoinflammatory fibroblastic sarcomas reveals a novel SND1::BRAF fusion and 3 different molecular aberrations with the potential to upregulate the TEAD1 gene including SEC23IP::VGLL3 and TEAD1::MRTFB gene fusions.
    Klubíčková N; Agaimy A; Hájková V; Ptáková N; Grossmann P; Šteiner P; Michal M; Michal M
    Virchows Arch; 2022 Oct; 481(4):613-620. PubMed ID: 35776191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors.
    Kao YC; Ranucci V; Zhang L; Sung YS; Athanasian EA; Swanson D; Dickson BC; Antonescu CR
    Am J Surg Pathol; 2017 Nov; 41(11):1456-1465. PubMed ID: 28692601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep sequencing of myxoinflammatory fibroblastic sarcoma.
    Arbajian E; Hofvander J; Magnusson L; Mertens F
    Genes Chromosomes Cancer; 2020 May; 59(5):309-317. PubMed ID: 31898851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent YAP1::MAML2 fusions in "nodular necrotizing" variants of myxoinflammatory fibroblastic sarcoma: a comprehensive study of 7 cases.
    Perret R; Tallegas M; Velasco V; Soubeyran I; Coindre JM; Azmani R; Baud J; Bacle G; De Pinieux G; Le Loarer F
    Mod Pathol; 2022 Oct; 35(10):1398-1404. PubMed ID: 35546636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in the Diagnosis, Pathogenesis, and Management of Myxoinflammatory Fibroblastic Sarcoma.
    Nishio J; Nakayama S; Aoki M
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases.
    Suster D; Michal M; Huang H; Ronen S; Springborn S; Debiec-Rychter M; Billings SD; Goldblum JR; Rubin BP; Michal M; Suster S; Mackinnon AC
    Mod Pathol; 2020 Dec; 33(12):2520-2533. PubMed ID: 32514165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VGLL3 operates via TEAD1, TEAD3 and TEAD4 to influence myogenesis in skeletal muscle.
    Figeac N; Mohamed AD; Sun C; Schönfelder M; Matallanas D; Garcia-Munoz A; Missiaglia E; Collie-Duguid E; De Mello V; Pobbati AV; Pruller J; Jaka O; Harridge SDR; Hong W; Shipley J; Vargesson N; Zammit PS; Wackerhage H
    J Cell Sci; 2019 Jul; 132(13):. PubMed ID: 31138678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor.
    Antonescu CR; Zhang L; Nielsen GP; Rosenberg AE; Dal Cin P; Fletcher CD
    Genes Chromosomes Cancer; 2011 Oct; 50(10):757-64. PubMed ID: 21717526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.
    Jang JS; Lee A; Li J; Liyanage H; Yang Y; Guo L; Asmann YW; Li PW; Erickson-Johnson M; Sakai Y; Sun Z; Jeon HS; Hwang H; Bungum AO; Edell ES; Simon VA; Kopp KJ; Eckloff B; Oliveira AM; Wieben E; Aubry MC; Yi E; Wigle D; Diasio RB; Yang P; Jen J
    Sci Rep; 2015 May; 5():9755. PubMed ID: 25985019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions.
    Hallor KH; Sciot R; Staaf J; Heidenblad M; Rydholm A; Bauer HC; Aström K; Domanski HA; Meis JM; Kindblom LG; Panagopoulos I; Mandahl N; Mertens F
    J Pathol; 2009 Apr; 217(5):716-27. PubMed ID: 19199331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGFBR3 and MGEA5 rearrangements are much more common in "hybrid" hemosiderotic fibrolipomatous tumor-myxoinflammatory fibroblastic sarcomas than in classical myxoinflammatory fibroblastic sarcomas: a morphological and fluorescence in situ hybridization study.
    Zreik RT; Carter JM; Sukov WR; Ahrens WA; Fritchie KJ; Montgomery EA; Weiss SW; Folpe AL
    Hum Pathol; 2016 Jul; 53():14-24. PubMed ID: 26980036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent VGLL3 fusions define a distinctive subset of spindle cell rhabdomyosarcoma with an indolent clinical course and striking predilection for the head and neck.
    Agaimy A; Dermawan JK; Leong I; Stoehr R; Swanson D; Weinreb I; Zhang L; Antonescu CR; Dickson BC
    Genes Chromosomes Cancer; 2022 Dec; 61(12):701-709. PubMed ID: 35766997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myxoinflammatory fibroblastic sarcoma: morphologic and genetic updates.
    Ieremia E; Thway K
    Arch Pathol Lab Med; 2014 Oct; 138(10):1406-11. PubMed ID: 25268202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR Activation Screening Identifies VGLL3-TEAD1-RUNX1/3 as a Transcriptional Complex for PD-L1 Expression.
    Wijdeven RH; Cabukusta B; Behr FM; Qiu X; Amiri D; Borras DM; Arens R; Liang Y; Neefjes J
    J Immunol; 2022 Sep; 209(5):907-915. PubMed ID: 35922063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The t(1;10)(p22;q24) TGFBR3/MGEA5 Translocation in Pleomorphic Hyalinizing Angiectatic Tumor, Myxoinflammatory Fibroblastic Sarcoma, and Hemosiderotic Fibrolipomatous Tumor.
    Liu H; Sukov WR; Ro JY
    Arch Pathol Lab Med; 2019 Feb; 143(2):212-221. PubMed ID: 29979612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma.
    Kao YC; Fletcher CDM; Alaggio R; Wexler L; Zhang L; Sung YS; Orhan D; Chang WC; Swanson D; Dickson BC; Antonescu CR
    Am J Surg Pathol; 2018 Jan; 42(1):28-38. PubMed ID: 28877062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
    Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
    Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant undifferentiated epithelioid neoplasms with MAML2 rearrangements: A clinicopathologic study of seven cases demonstrating a heterogenous entity.
    Dermawan JK; DiNapoli SE; Sukhadia P; Mullaney KA; Gladdy R; Healey JH; Agaimy A; Cleven AH; Suurmeijer AJH; Dickson BC; Antonescu CR
    Genes Chromosomes Cancer; 2023 Apr; 62(4):191-201. PubMed ID: 36344258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
    Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
    Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.
    Tomić TT; Olausson J; Wilzén A; Sabel M; Truvé K; Sjögren H; Dósa S; Tisell M; Lannering B; Enlund F; Martinsson T; Åman P; Abel F
    PLoS One; 2017; 12(4):e0175638. PubMed ID: 28448514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.